Aimmune Therapeutics, Inc.

Just a month after expressing “substantial doubt regarding its ability to continue as a going concern,” DBV Technologies shares are soaring on the news that the French firm has reached agreement with

The US Food and Drug Administration’s vaccines advisory committee now will handle allergenic products following the termination of a panel created 40 years ago to deal with the rarely seen application

The US Food and Drug Administration will likely bring any promising biomarkers for allergy and asthma treatments to an advisory committee review before endorsing their use for regulatory purposes. “If

The news that Novartis AG has terminated a late-stage peanut allergy trial of one of its more closely watched assets, ligelizumab, looks like good news for other players in the space, notably DBV T